Aptose Biosciences Stock Price and Value Analysis

Should you buy Aptose Biosciences stock? (NasdaqCM:APTO). Let's see how it does in our automated value investing analysis system.

  • This company has amazingly consistent growth!
  • This company is not making money.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the APTO Numbers

APTO Price
(Aptose Biosciences stock price per share)
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 2%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 3,068,086 shares shorted. With 68,642,837 shares available for purchase and an average trading volume over the past 10 trading days of 1,747,570, it would take at least 1.756 days for all of the short holders to cover their shorts.

Is Aptose Biosciences Stock on Sale?

Based on our analysis, we believe that you should not buy Aptose Biosciences right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy APTO Stock?

Does Aptose Biosciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.